Targeted therapy for soft tissue sarcomas in adolescents and young adults

Diana A Steppan, Christine A Pratilas, David M Loeb Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors originating from the mesenchyme...

Full description

Bibliographic Details
Main Authors: Steppan DA, Pratilas CA, Loeb DM
Format: Article
Language:English
Published: Dove Medical Press 2017-03-01
Series:Adolescent Health, Medicine and Therapeutics
Subjects:
Online Access:https://www.dovepress.com/targeted-therapy-for-soft-tissue-sarcomas-in-adolescents-and-young-adu-peer-reviewed-article-AHMT
id doaj-a1241be507b94a359737e933f6e837f4
record_format Article
spelling doaj-a1241be507b94a359737e933f6e837f42020-11-24T20:59:22ZengDove Medical PressAdolescent Health, Medicine and Therapeutics1179-318X2017-03-01Volume 8415532127Targeted therapy for soft tissue sarcomas in adolescents and young adultsSteppan DAPratilas CALoeb DMDiana A Steppan, Christine A Pratilas, David M Loeb Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors originating from the mesenchyme. Even though they affect individuals in all age groups, the prevalence of subtypes of STSs changes significantly from childhood through adolescence into adulthood. The mainstay of therapy is surgery, with or without the addition of chemotherapy and/or radiation therapy. These treatment modalities are associated, in many cases, with significant morbidity and, given the heterogeneity of tumor histologies encompassed by the term “STS”, have not uniformly improved outcomes. Moreover, some subgroups of STSs appear to be more, and others less, responsive to conventional chemotherapy agents. Over the last two decades, our understanding of the biology of STSs is slowly increasing, allowing for the development of more targeted therapies. We review the new treatment modalities that have been tested on patients with STSs, with a special focus on adolescents and young adults, a group of patients that is often underrepresented in clinical trials and has not received the dedicated attention it deserves, given the significant differences in biology and treatment response in comparison to children and adults. Keywords: synovial sarcoma, MPNST, soft tissue sarcoma, targeted therapyhttps://www.dovepress.com/targeted-therapy-for-soft-tissue-sarcomas-in-adolescents-and-young-adu-peer-reviewed-article-AHMTsynovial sarcomaMPNSTsoft tissue sarcomatargeted therapy
collection DOAJ
language English
format Article
sources DOAJ
author Steppan DA
Pratilas CA
Loeb DM
spellingShingle Steppan DA
Pratilas CA
Loeb DM
Targeted therapy for soft tissue sarcomas in adolescents and young adults
Adolescent Health, Medicine and Therapeutics
synovial sarcoma
MPNST
soft tissue sarcoma
targeted therapy
author_facet Steppan DA
Pratilas CA
Loeb DM
author_sort Steppan DA
title Targeted therapy for soft tissue sarcomas in adolescents and young adults
title_short Targeted therapy for soft tissue sarcomas in adolescents and young adults
title_full Targeted therapy for soft tissue sarcomas in adolescents and young adults
title_fullStr Targeted therapy for soft tissue sarcomas in adolescents and young adults
title_full_unstemmed Targeted therapy for soft tissue sarcomas in adolescents and young adults
title_sort targeted therapy for soft tissue sarcomas in adolescents and young adults
publisher Dove Medical Press
series Adolescent Health, Medicine and Therapeutics
issn 1179-318X
publishDate 2017-03-01
description Diana A Steppan, Christine A Pratilas, David M Loeb Division of Pediatric Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA Abstract: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors originating from the mesenchyme. Even though they affect individuals in all age groups, the prevalence of subtypes of STSs changes significantly from childhood through adolescence into adulthood. The mainstay of therapy is surgery, with or without the addition of chemotherapy and/or radiation therapy. These treatment modalities are associated, in many cases, with significant morbidity and, given the heterogeneity of tumor histologies encompassed by the term “STS”, have not uniformly improved outcomes. Moreover, some subgroups of STSs appear to be more, and others less, responsive to conventional chemotherapy agents. Over the last two decades, our understanding of the biology of STSs is slowly increasing, allowing for the development of more targeted therapies. We review the new treatment modalities that have been tested on patients with STSs, with a special focus on adolescents and young adults, a group of patients that is often underrepresented in clinical trials and has not received the dedicated attention it deserves, given the significant differences in biology and treatment response in comparison to children and adults. Keywords: synovial sarcoma, MPNST, soft tissue sarcoma, targeted therapy
topic synovial sarcoma
MPNST
soft tissue sarcoma
targeted therapy
url https://www.dovepress.com/targeted-therapy-for-soft-tissue-sarcomas-in-adolescents-and-young-adu-peer-reviewed-article-AHMT
work_keys_str_mv AT steppanda targetedtherapyforsofttissuesarcomasinadolescentsandyoungadults
AT pratilasca targetedtherapyforsofttissuesarcomasinadolescentsandyoungadults
AT loebdm targetedtherapyforsofttissuesarcomasinadolescentsandyoungadults
_version_ 1716782685718839296